SELECT-GCA Period 2 (52-104 weeks) trial outcomes: Compared a strategy of continuing or stopping Upadacitinib in GCA patients in remission at 52 weeks. Patients were more likely to maintain remission and less likely to flare if they continued on Upadacitinib 15 mg daily (flare rate 16%) than if they swapped to…
Read More
Last week our team published a new finding in eosinophilic granulomatosis with polyangiitis (EGPA), the demonstration of large vasculitis on PET/CT scan. EGPA is typically thought to involve small vessels only and this new finding may help to explain why some patients with EGPA experience blockages and clots in their large…
Read More
The rheumatology and nuclear medicine units at Prince of Wales Hospital work closely together to diagnose and monitor patients with large vessel vasculitis. We use PET scans as our first line investigation for new and relapsed giant cell arteritis (GCA). In some cases the PET scan not only excludes GCA…
Read More
I’m excited to share that the Australian and New Zealand Vasculitis Society (ANZVASC) is hosting its annual symposium for clinicians and researchers at Prince of Wales Hospital on Saturday 14th October. It promises to be an excellent meeting with speakers addressing topics on ANCA and large vessel vasculitis. I’m especially looking…
Read More
Last week I had the privilege of presenting on “Challenges in GCA Clinical Practice: Navigating Therapy” alongside Dr Clare Owens and A/Prof Jason Chuen at the 2023 Australian Rheumatology Association annual conference in Hobart. As most people who have GCA, or look after patients with GCA know, Tocilizumab is generally a…
Read More
The treatment and understanding of ANCA associated vasculitis (AAV) continues to evolve. I’m in the middle of watching an AAV session at the American College of Rheumatology 2022 meeting and felt inspired to share some newer Rituximab related insights. Firstly, as of September 2022, Rituximab now has an unrestricted listing under…
Read More
